Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
BUSINESS
Nippon Shinyaku’s DMD Drug Misses Mark in Confirmatory Study
Nippon Shinyaku said on May 27 that its Duchenne muscular dystrophy (DMD) drug Viltepso (viltolarsen) failed to meet the primary endpoint in a global confirmatory study. Despite the setback, the company says it stands behind the benefits of the exon-skipping…
To read the full story
Related Article
- Label Revised for DMD Drug Viltepso Based on PIII Miss
August 18, 2026
- Nippon Shinyaku Chief Defends Benefits of DMD Therapy after PIII Miss
May 29, 2024
- Viltepso Now Available in US: Nippon Shinyaku
August 21, 2020
- Nippon Shinyaku’s DMD Treatment Approved in US
August 17, 2020
- Nippon Shinyaku’s DMD Drug Now Available in Japan; AZ’s Lokelma, Ono’s Velexbru Too
May 21, 2020
BUSINESS
- Lilly, Tanabe Signal Supply Restrictions over Suspected Mounjaro Misuse
November 9, 2026
- Celltrion to Lift Shipment Curbs on Japan’s 1st Actemra Biosimilar
November 9, 2026
- AstraZeneca Vows to Back Japanese Innovation with Global Potential
November 9, 2026
- Nippon Shinyaku Flags Possible IR Data Leak
November 9, 2026
- Espha Debuts NorLevo Generic in Japan
November 9, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…